Antonio Arcadipane

Antonio Arcadipane

Auto-generated profile, based on publicly available information

Antonio Arcadipane

Department of Anesthesia and Intensive Care, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT-IRCCS), Palermo, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GMGennaro Martucci
Gennaro Martucci
MGMarco Giani
Marco Giani
MSMatthieu Schmidt
Matthieu Schmidt
KTKenichi Tanaka
Kenichi Tanaka
ATAli Tabatabai
Ali Tabatabai
I(International ECMO Network (ECMONet)
International ECMO Network (ECMONet)
Definitive guidelines for anticoagulation management during veno-venous extracorporeal membrane oxygenation (VV ECMO) are lacking, while bleeding complications continue to pose major challenges. To describe anticoagulation modalities and bleeding events in adults receiving VV ECMO. International prospective observational study in 41 centers, from December 2018 to February 2021. Anticoagulation was recorded daily in terms of type, dosage, and monitoring strategy. Bleeding events were reported according to site, severity, and impact on mortality. The study cohort included 652 patients, and 8471 days on ECMO were analyzed. Unfractionated heparin (UFH) was the initial anticoagulant in 77% of patients, and the most used anticoagulant during the ECMO course (6221 days, 73%). Activated partial thromboplastin time (aPTT) was the most common test for monitoring coagulation (86% of days): the median value was 52 seconds (39-61), but dropped by 5.3 seconds after the first bleeding event (95% CI -7.4 to -3.2, p< 0.01). Bleeding occurred on 1202 days (16.5 %). Overall, 342 patients (52.5 %) experienced at least one bleeding event (one episode every 215 hours on ECMO), of which 10 (1.6%) were fatal. In a multiple penalized Cox proportional hazard model, higher aPTT was a potentially modifiable risk factor for the first episode of bleeding (for 20 seconds increase, hazard ratio 1.07). Anticoagulation during VV ECMO was a dynamic process, with frequent stopping in cases of bleeding, and restart according to the clinical picture. Future studies might explore lower aPTT targets to reduce the risk of bleeding.

15 November 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
AMalessandra mularoni
alessandra mularoni
ACandrea cona
andrea cona
MBMatteo Bulati
Matteo Bulati
RBRosalia Busà
Rosalia Busà
MMMonica Miele
Monica Miele
MLMario Luppi
Mario Luppi
Kaposi sarcoma herpesvirus/human herpesvirus-8 (HHV-8) neoplastic and non-neoplastic disease in solid organ transplant (SOT) recipients can be life-threatening. We evaluated the seroprevalence of HHV-8 infection among donors (D) and recipients (R), the incidence of HHV-8 transmission/reactivation, and the clinical characteristics, management, and outcomes of HHV-8-related diseases, including Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome (KICS), in consecutive SOT patients from 2011 to 2023. HHV-8 seroprevalence was 3.3% in 1349 donors and 8.4% in 1856 recipients screened (p<0.0001). Among the D+/R- group (n=49), 13 patients developed HHV-8-related diseases: 7 liver recipients had KICS, and 1 lung recipient had Kaposi sarcoma (KS) with subsequent KICS. Four KICS patients treated with rituximab survived, while the 3 patients not treated with rituximab died. Within the D-/R- group, out of 5 (0.3%) patients with non-donor-derived primary HHV-8 infection, 3 liver recipients developed KICS. In the R+ patients (n=155), 3 developed KS. In our cohort, 25/944 (2.6%) liver transplant recipients had a primary HHV-8 infection, and 10 of them (40%) developed KICS; 40% (4/10) of HHV-8 seropositive heart transplant recipients developed reactivation and 2 of them (50%) had fatal KS. Serologic screening and molecular surveillance of D+/R- patient groups facilitate early recognition and effective therapy of KICS.

1 April 2021 in Intensive and Critical Care Nursing
Verified
Journal Article
Closed access
ECElena Conoscenti
Elena Conoscenti
GMGennaro Martucci
Gennaro Martucci
MPMarcello Piazza
Marcello Piazza
FTFabio Tuzzolino
Fabio Tuzzolino
BRBarbara Ragonese
Barbara Ragonese
GCGiuseppe Chiaramonte
Giuseppe Chiaramonte

11 December 2019 in Turkish Journal of Anaesthesiology and Reanimation
Verified
Journal Article
Closed access
Filippo SanfilippoFilippo Sanfilippo
Filippo Sanfilippo
FSFrancesco Sgalambro
Francesco Sgalambro
GCGiuseppe Chiaramonte
Giuseppe Chiaramonte
ICIrccs-Ismett (Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione) “Renato Fiandaca” Simulation Center
Irccs-Ismett (Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione) “Renato Fiandaca” Simulation Center
CSCristina Santonocito
Cristina Santonocito
AAAntonio Arcadipane
Antonio Arcadipane
There are several airway devices available for difficult tracheal intubation (DTI) management, but the failure rate remains high. The use of laryngoscopy to facilitate the fibreoptic-bronchoscope intubation (CLBI) has been increasingly reported in DTI situations, but it has not been formally studied yet. We designed a single-centre simulation study on DTI (neck rigidity and tongue oedema) comparing three techniques: direct laryngoscopy (DL), video-laryngoscopy (VLS) and CLBI. Eighteen anaesthesiologists naïve to VLS/CLBI approaches, participated in the study. The primary outcome was the intubation rate at the first attempt. Secondary outcomes were an overall time-to-intubate (TTI) and time-to-ventilate (TTV), success at the second and third attempt and ease of intubation as evaluated by a subjective 5-point Likert scale. The CLBI technique had a higher success rate at the first attempt than DL (66% vs 22%, p=0.007), while VLS did not (44%, p=0.16). A trend towards higher success at the third attempt was found for both VLS and CLBI vs DL (p=0.07 and p=0.06, respectively). The VLS had a shorter overall TTV than DL (88±60 vs 121±59 sec, respectively, p=0.04) and a trend towards a shorter TTI (81±61 vs 116±64 sec, respectively, p=0.06). The CLBI approach showed a non-significantly lower TTI/TTV as compared to DL (p=0.10 and p=0.16, respectively). Anaesthesiologists judged that the intubation with VLS (3.7±1.0) and CLBI (3.8±1.0) was easier than with DL (1.7±0.8, both p<0.001). In a simulated DTI scenario, CLBI had a higher success rate at the first attempt than DL, while VLS did not. By the third attempt, both rescue techniques had a trend towards a higher success rate than DL. The CLBI technique seems a promising alternative for the management of DTI.

31 January 2009 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
GDGiuseppe D’Ancona
Giuseppe D’Ancona
MPMatteo Parrinello
Matteo Parrinello
GSGianluca Santise
Gianluca Santise
DBDomenico Biondo
Domenico Biondo
FPFrancesco Pirone
Francesco Pirone
MPMichele Pilato
Michele Pilato

1 July 2018 in Transplantation
Verified
Journal Article
Closed access
ABAlessandro Bertani
Alessandro Bertani
LMLavinia De Monte
Lavinia De Monte
EREMANUELE RUSSO
EMANUELE RUSSO
RFRaffaele Francesco
Raffaele Francesco
PVPatrizio Vitulo
Patrizio Vitulo
PGPanarello Giovanna
Panarello Giovanna
Bridge with artificial respiratory support, although now widely used, may significantly affect the results of lung transplantation (LTX), particularly in limited-volume centers. Between 2006 and 2016, 155 patients underwent lung transplantation at our center. 50 patients were bridged to possible transplantation with venovenous or venoarterial ECMO. 32 patients (64%) were successfully bridged to transplantation while 18 died on the waiting list. Overall, lung transplants after ECMO repesented 21% of all the entire transplant cohort. The average duration of ECMO support was 7 days (range 1-30). The majority (50%) of patients had cystic fibrosis. Awake ECMO was used in 8 cases before transplantation. Our supported patients had a trend to less favorable but statistically equivalent 1-, 3-, and 12-month survival compared with non-supported patients. The incidence of primary graft dysfunction (PGD) of any grade was higher in supported patients, but the rate of high-grade PGD (>2) was similar in all patients. The length of stay in the intensive care unit was 10 days longer, on average, in bridged patients. After 2010, patients bridged to LTX on ECMO received an emergency status on the waiting list. Competitive risk analysis was used to assess the overall benefit of performing transplantation in patients who were placed on ECMO and on an emergency status. The entire population of patients who were listed for LTX since the beginning of the program was analyzed. Death was the event of interest and LTX the competing event of the model. Patients on the list before 2010 and without ECMO support had the highest cumulative incidence of death and the least probability to receive a transplant (figure 1). These findings support the use of ECMO as a bridge to LTX and the overall benefit of an emergency allocation system, without any increased risk of significant worse outcome in patients who are not bridged.